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Abstract
Background: People with diabetes who experience an acute myocardial infarction (AMI) have a higher risk of
death and recurrence of AMI. This study was commissioned by the Department for Transport to develop survival
tables for people with diabetes following an AMI in order to inform vehicle licensing.
Methods: A cohort study using data obtained from national hospital admission datasets for England and Wales
was carried out selecting all patients attending hospital with an MI for 2003-2006 (inclusion criteria: aged 30+
years, hospital admission for MI (defined using ICD 10 code I21-I22). STATA was used to create survival tables and
factors associated with survival were examined using Cox regression.
Results: Of 157,142 people with an MI in England and Wales between 2003-2006, the relative risk of death or
recurrence of MI for those with diabetes (n = 30,407) in the first 90 days was 1.3 (95%CI: 1.26-1.33) crude rates and
1.16 (95%CI: 1.1-1.2) when controlling for age, gender, heart failure and surgery for MI) compared with those without
diabetes (n = 129,960). At 91-365 days post AMI the risk was 1.7 (95% CI 1.6-1.8) crude and 1.50 (95%CI: 1.4-1.6) adjusted.
The relative risk of death or re-infarction was higher at younger ages for those with diabetes and directly after the AMI
(Relative risk; RR: 62.1 for those with diabetes and 28.2 for those without diabetes aged 40-49 [compared with
population risk]).
Conclusions: This is the first study to provide population based tables of age stratified risk of re-infarction or death
for people with diabetes compared with those without diabetes. These tables can be used for giving advice to
patients, developing a baseline to compare intervention studies or developing license or health insurance
guidelines.
Background
Patients with diabetes who have an acute myocardial
infarction (AMI) are at higher risk of death, both in the
acute phase [1] and during follow-up [2-4]. In fact, car-
diovascular disease is reported to account for almost
80% of all ‘diabetic’ deaths[5]. This may be because
patients with diabetes often have a cluster of risk factors
including hypertension, hypercholesterolemia, obesity,
hyperglycemia, high risk lifestyle factors (such as smok-
ing), albuminuria, and family history of disease [6] and
have a more complications in hospital following an MI
[7]. For example, heart failure is twice as common in
patients with type 2 diabetes [8] compared with those
without type 2 diabetes. Thus, the short term mortality
rate of a patient with diabetes is reported to be twice
that in those without diabetes [9,10] and patients with
diabetes have reduced long term survival [2,11]. The
relative risk of a primary MI is more common among
women with type 2 diabetes than among men [12] How-
ever, there are currently few population-based estimates
of the probability of survival following an AMI for
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diabetes [2,13] and none look at time to re-infarction.
This study was developed from a project commis-
sioned by the UK Department for Transport [14] to
develop absolute and relative risk survival tables to show
time to death or recurrence of an AMI for diabetic and
non-diabetic patients hospitalised for AMI. It presents
absolute risk reference tables for people who experience
an AMI stratified by age, sex and diabetes and separately
absolute risk reference tables for controls who have not
experienced a primary AMI.
Methods
Design
We conducted a cohort study of risk of death or recur-
rence of MI in people hospitalised for MI using all hospital
admissions in England and Wales for the years 2003-2006.
Datasets
Data were obtained from two hospital admission data-
sets; PEDW - Patient Episode Database for Wales and
HES - Hospital Episode Statistics for England. These
datasets are publicly available on request to the data
custodians. MI was defined using ICD code I21-I22 and
diabetes using ICD 10 codes E10-E14. HES and PEDW
records are held at a ‘finished consultant episode’ (FCE)
level, which represent periods of care under a particular
consultant while in hospital. One admission might
therefore, result in more than one FCE. These FCE’s
were internally linked to develop ‘hospital spells’ for an
individual and ‘super-spells’ that link hospital spells for
patients transferred between hospitals during their index
admission. Super-spells are records which give the entire
patient journey through the hospital system. Data con-
tained on the hospital admission systems includes
demographics, diagnosis, surgery, admission and dis-
charge information but it does not include prescriptions,
symptoms or laboratory or other tests.
Study population
Patients admitted to hospital who were aged less than
30 years were excluded from the study. Diabetes was
defined as ICD codes E10-E14 (Insulin dependent, non-
insulin dependent, malnutrition-related diabetes melli-
tus, other specified diabetes, and other non-specified
diabetes). Surgery for the current MI was recorded
(OPCS codes K40 to K50 and K75) which includes
angioplasty, CABG and stent placement. All patients
were taken from admission to hospital for an AMI
between the dates 2003-2006.
Linkage
An anonymised version of the PEDW database was
linked with the Welsh NHS Administrative Register (AR)
which records date of death or date of moving out
of Wales. Therefore, an accurate estimation of death, or
loss to follow-up due to leaving Wales, can be calculated.
The HES dataset was linked with individual records of
mortality held by the Office for National Statistics (ONS)
using unique National Health Service (NHS) numbers
[14]. Recurrent AMIs can be identified from readmis-
sions to hospital. Patients who suffer AMI and die before
reaching hospital cannot be identified by hospital-based
systems, but can be identified using mortality data from
AR and ONS. While there may be an underestimate of
the number of re-infarctions the combined endpoint of
re-infarction/death will include MI’s resulting in death
(without hospital admission). In the HES system patients
who have moved out of England cannot be identified.
This could have the effect of making the incidence
of re-infarction and death slightly lower, since patients
moving outside the UK who have an AMI or die cannot
be identified. However, the number of people who
m o v e do u to fE n g l a n da r er e l a t i v e l ys m a l la n dt h e r e f o r e
unlikely to change the validity of the conclusions. In
addition, patients who have a silent AMI, that is have a
re-infarction but are not admitted and do not die, will be
missed from this study.
Control group
The entire Welsh population was selected using people
on the Welsh AR and those who were not recorded as
having had an MI before the 1
st of January 2003 were
extracted. The rate of AMI and death in this control
group was determined using the same methods as those
for the AMI patients. The control group provided popu-
lation-based incidence rates of first AMI or mortality in
those without an index AMI since 1996.
Quality of the datasets
Data from the Myocardial Ischaemia National Audit
Project (MINAP) data [15] was obtained, with permis-
sion from the data guardians, for the period 1st April
2003-31
st March 2006 in order to examine validity of
data held in the hospital admissions dataset. MINAP is
a dataset of patients hospitalised with AMI which is
used to compare the management of myocardial infarc-
tion within hospitals against targets specified by the
National Service Framework for Coronary Heart Disease
(NSF). This dataset is not a population register of AMI
as it is known that participation and recruitment differs
by hospital (for example percentage of non-STEMI MI’s
varies between hospitals from 0.8%-73%)[14]. The origi-
nal reason for setting up MINAP was the measurement
of the process and outcomes of the care of patients with
MIs amenable to reperfusion treatment. Non-STEMI is
not managed by reperfusion therapy and so some hospi-
tals have tended not to record data for this type of heart
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MINAP. However, we have used this database to exam-
ine if all MI’s found in MINAP can be also found in
PEDW. This dataset was linked with the Welsh hospital
admission system (PEDW) using anonymised and
encrypted NHS numbers to examine the extent of over-
lap, coding coherence and accuracy.
In addition, the out-patients clinical care system used
by the diabetologists was linked with the hospital admis-
sions system to examine the number of known diabetic
patients (as identified from the diabetes clinical care
system) who had any mention of diabetes in their
admission to hospital.
Statistical analysis
STATA was used with the st command to examine sur-
vival (death alone or death and re-infarction) for
patients stratified by age, sex and diabetes. Survival was
analysed for the first 90 days, 91-180 days and 181-365
days. Factors associated with survival (diabetes, heart
failure, age, gender and surgery [angioplasty/stenting, for
the current MI]) were analysed using Cox regression.
Interaction terms have not been included in the model
as given the large numbers of patients all interaction
terms are found to be significant and make interpreta-
tion of the model very difficult. Proportionality was
examined by comparing graphs of the scaled Schoenfeld
residuals.
Results
Data quality
In Wales, of 3,371 individuals recorded in MINAP
attending Welsh hospitals, 3368 (99.91%) were also
found in PEDW, 2,987 (89%) were found in PEDW with
a diagnosis of AMI, 366 (10.9%) were recorded in
PEDW but with a non AMI diagnosis (e.g. diagnosed
with chronic ischemic heart disease or angina pectoris),
3.9% [15] were recorded as attending an English hospital
with AMI and 3 (0.1%) were recorded in MINAP but
missing from PEDW altogether.
There was no significant difference between the num-
ber of people recorded in MINAP as having diabetes
(1620/8143 - 19.9%) compared with the number
recorded on the hospital admission system, PEDW
(30,407/160,367 - 20%). Thus, there is no evidence of
relative under ascertainment of diabetes when using the
hospital admission systems. In addition, of 853 patients
who had diabetes (as confirmed on the out-patients dia-
betologist clinical care system) and who had an in-
patient hospital visit (either related or not related to the
diabetes), 774 (90%) had diabetes recorded during their
hospital visit (for MI, cataract surgery, amputation).
Finally, in Wales, the number of people who moved out-
side of Wales in a 1 year period was 1.2%. We would
expect the numbers moving out of the UK to be of similar
levels[16]. Thus, the error level in the patients from the
England system is likely to be small.
Demographics
There were 30,407 (19%) people with diabetes (37.9%
female, average age 70 (min-max: 30-120) and 129,960
(81%) people (35% female, average age 68.7 (min-max:
30-105) without diabetes. Among those with diabetes;
34.3% had heart failure and 15.3% had heart surgery for
the MI. Among those without diabetes 20.6% had heart
failure and 16.2% had heart surgery.
Survival
There were 157,142 people followed for 126,731 follow-
up years within England and Wales. An additional 3225
were included in the dataset but had no follow-up time as
they died on the date of admission (2%), 8 patients were
not followed as they were recorded as having moved out
of Wales/UK and before the date of their admission for
their MI. Within this timeframe there were 48,517 deaths
or re-infarction events, giving an incidence of 38.3% (95%
CI: 37.9-38.6) per person year of follow-up. The risk of
death was highest in the first 90 days [Table 1], and then
declined. However, the risk of re-infarction remained
high for the first 180 days (Figure 1). The combined rate
of death or re-infarction was highest for those with
diabetes [Table 2]. Patientsw i t hd i a b e t e sw e r ea t1 . 1 6
(95%CI: :1.1-1.2) times higher risk of death or re-infarc-
tion in the first 90 days, and at 1.5 (95%CI: 1.4-1.6) times
higher risk at 90-365 days post MI, when controlling for
age, gender, heart failure and heart surgery [Table 3].
Therefore, the attributable risk of the diabetes increases
90 days post MI. However, this is because the absolute
risk of death in the non diabetic group declines greatly
with time (see Figure 1).
The population risk is given in Table 4 and the rela-
tive risk compared with population rates is given in
Table 5. The risk attributable to having an AMI is high-
est in younger ages and directly after the MI (relative
risk of death or re-infarction is 82.3 among women aged
40-49 with no diabetes at 0-90 days compared with 1.1
for women aged 90 at 181-365 days. The relative risk
for those with diabetes is highest for younger patients.
For example, there is a 2 fold higher risk of death or
re-infarction for males with diabetes aged 50-59 at 0-90
days post MI (compared with those without diabetes,
38/18.6 = 2.0 (95%CI: 1.6-2.7) higher risk -Table 5).
However, in males aged 90+ there is no increased risk
associated with having diabetes. (12.5/11.9 = 1.05 (95%
CI: 0.82-1.9) at 0-90 days. Thus, the relative risk of mor-
tality/re-infarction is more prominent in younger indivi-
duals with diabetes because the risk in controls is so
much lower at a younger age. Age is a very strong
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the absolute risk of these outcomes almost doubles with
each age decade (Table 1 and 2).
Although female gender carries a risk of 1.6 that of
males in unadjusted analysis, after correction for age,
this factor is no longer significant (Table 3).
Discussion
This study presents population based figures for risks of
recurrence of MI or death for 30,407 people with diabetes
following an MI compared with those without diabetes.
These tables can give the absolute risks and the relative
risks of MI and/or death stratified by age and sex. Findings
suggest that diabetes is an important risk factor for
younger patients and is associated with poorer outcome
especially for re-infarction. This is supported by the find-
ing that many young people experiencing MI have undiag-
nosed diabetes but an absence of other risk factors [17].
Risk factors specifically associated with diabetes include
diabetes increased atherosclerotic plaque formation and
thrombosis [18] associated with hypergycemia [19].
The control population risk is constant with time
(e.g. 0.46 per 1,000 in the age 30-39 over 0-90 days and
0.71 over 181-365 days (0.36 per 1,000 if this is taken as a
9 0d a yp e r i o d -T a b l e4 ) .T h e r ea r en oe x i s t i n gs t u d i e s
showing survival to re-MI in a population based study [11].
Thus, this study provides survival tables that can be used
to improve information regarding prognosis for patients, to
inform treatment strategies for people having an AMI and
to inform driver licensing and insurance guidelines. This is
a population based study based on 30,407 people with dia-
betes. No other study has looked at a total population
cohort to give rates of recurrence of infarction stratified by
age and sex. This data is not possible to generate using
meta-analysis of existing cohort studies [20] and can only
be developed using routinely collected data.
Data on mortality are comparable to that previously
published showing a 2 fold increase in mortality in the
Table 1 Mortality rates following an AMI per 1,000 people
Gender and Co-morbidity Age 0-90 days:
rate (95% CI)
n 91-180 days:
rate (95% CI)
n 181-365 days:
rate (95% CI)
n
Male
No diabetes 30-39 13 (9-20) 1,635 1.5 (0.3-6.0) 1414 2.1(0.8-5.6) 1226
40-49 17 (14-20) 7,894 3.5 (2.3-5.3) 6784 3.6 (2.5-5.1) 5722
50-59 33 (30-36) 15,712 4.5 (3.5-5.9) 13276 4.3 (3.5-5.4) 11306
60-69 77 (73-82) 18,701 15 (12-17) 15204 14 (12-16) 12761
70-79 197 (190-203) 19,714 39 (36-42) 14224 37 (34-40) 11770
80-89 395(383-407) 14,732 85 (79-92) 8904 91 (85-97) 6989
90+ 705 (665-749) 2,548 170 (140-190) 1192 160 (140-190) 870
Diabetes 30-39 19 (6-59) 170 15 (3.6-58) 150 5.3 (0.7-37.9) 123
40-49 36 (25-51) 987 5 (2-14) 811 11 (5.9-19) 701
50-59 67 (57-79) 2626 15 (11-22) 2120 14(10-19) 1808
60-69 135 (124-147) 4496 25 (20-32) 3433 32 (27-38) 2875
70-79 266 (251-280) 6133 62 (54-70) 4175 55 (49-62) 3374
80-89 416 (392-442.3) 3528 130 (110-140) 2074 110 (95-120) 1529
90+ 704(604-817) 402 250 (180-340) 190 160 (110-230) 124
Female
No diabetes 30-39 25 (13-50) 344 3.7 (0.5-26.3) 293 2.6 (0.3-18.6) 252
40-49 28 (21-38) 1593 6.4 (3.2-12.9) 1341 4.7 (2.3-9.3) 1130
50-59 51 (44-59) 3754 8.4 (5.6-12.6) 3117 6.2 (4.2-9.3) 2620
60-69 88 (81-96) 7131 14(11-17) 5690 16 (14-20) 4795
70-79 216 (207-225) 13298 38 (34-42) 9457 34 (31-38) 7747
80-89 403 (391-415) 16908 78 (72-84) 10160 73 (69-79) 8074
90+ 629.9 (604-656) 5682 140 (120-150) 2853 130 (110-140) 2179
Diabetes 30-39 88 (37-212) 61 0 (0-0) 53 45 (15-140) 46
40-49 73 (47-115) 290 28 (13-62) 235 17 (7.2-41) 193
50-59 94 (74-119) 830 31 (20-49) 668 26 (17-39) 559
60-69 172 (153-193) 2081 30 (22-40) 1532 32 (25-41) 1270
70-79 277 (259-296) 4093 58 (49-68) 2749 60 (52-69) 2201
80-89 419 (396-444) 3848 100 (91-120) 2240 110 (93-120) 1714
90+ 665 (600-738) 848 190 (150-240) 414 180 (140-220) 288
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Page 4 of 8short term [9,10] and 40% increase in the longer term
[2,13] for MI patients with and without diabetes.
However, using routine data does have its limitations.
Coding and recording of all AMI’s in the hospital
admissions dataset is not perfect and there may be an
underestimate of number of AMI’s by approximately
10%, as some MI’s are recorded using imprecise coding.
In addition, approximately 10% of the ‘non-diabetes’
group may have had diabetes but the code was missing
from the hospital admission data.
Calculating unbiased population risks is difficult due
to absence of disease registers with 100% coverage and
selection bias[20] and restricted inclusion criteria may
lead to distorted risks. Therefore, routinely collected
data, although imperfect, is currently the closest
we have to a population based disease register which
supports low cost analysis of up to date and current
rates of disease and survival times for hospitalised MI.
However, to fully understand the explanatory or con-
founding factors and to incorporate them into a multi-
variate cox regression analysis, linkage is needed with
more data sources. For example factors which need to
be incorporated would include; other co-morbidities
(peripheral arterial disease, chronic pulmonary disease,
hypertension, hyperlipidemia, chronic kidney disease
and others), lifestyle factors (smoking, diet, physical
activity, physiotherapy), treatments prescribed (beta
blockers, streptokinase, aspirin, statins (pre and post
Rate of MI among men aged 70-79
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Figure 1 Rate of MI or death with time. (Males aged 70-79).
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Page 5 of 8Table 2 Mortality and re-infarction rate following a AMI per 1,000 people
Gender and Co-morbidity Age 0-90 days:
rate (95% CI)
n 91-180 days:
rate (95% CI)
n 181-365 days:
rate (95% CI)
n
Male
No diabetes 30-39 20 (14-28) 1635 9.1 (5.2-16) 1414 4.8 (2.5-9.2) 1226
40-49 24 (20-28) 7894 9.5 (7.3-12.2) 6784 8.9 (7.1-11.1) 5722
50-59 43 (40-46) 15712 11 (9.5-13) 13276 8.6 (7.3-10.1) 11306
60-69 88 (84-93) 18701 24 (21-27) 15204 20 (18-22) 12761
70-79 213 (206-221) 19714 56 (52-60) 14224 49 (46-52) 11770
80-89 421 (409-434) 14732 113 (106-121) 8904 110 (100-120) 6989
90+ 735 (693-779) 2548 202 (176-232) 1192 190 (170-220) 870
Diabetes 30-39 19 (6-59) 170 29 (11-78) 150 5.34 (0.75-38) 123
40-49 53 (40-70) 987 12 (6-23) 811 24 (16-36) 701
50-59 87 (76-100) 2626 28 (21-36) 2120 22 (17-29) 1808
60-69 154 (142-167) 4496 47 (40-55) 3433 46 (40-53) 2875
70-79 292 (277-307) 6133 90 (81-100) 4175 75 (68-84) 3374
80-89 453 (427-480) 3528 174 (156-195) 2074 150 (140-170) 1529
90+ 701 (634-776) 402 301 (226-402) 190 190 (130-270) 124
Female
No diabetes 30-39 25 (13-50) 344 11 (3.6-35) 293 5.2 (1.3-21) 252
40-49 38 (29-49) 1593 14 (8.6-22) 1341 9.9 (6.1-16) 1130
50-59 60 (51-68) 3754 13 (12-21) 3117 12 (9-16) 2620
60-69 100 (93-108) 7131 25 (21-29) 5690 21 (18-25) 4795
70-79 232 (223-241) 13298 54 (49-59) 9457 46 (42-50) 7747
80-89 424 (412-435) 16908 103 (97-110) 10160 93 (87-98) 8074
90+ 646 (620-673) 5682 165 (150-182) 2853 140 (130-160) 2179
Diabetes 30-39 88 (37-212) 61 21 (2.9-148) 53 60 (23-160) 46
40-49 100 (68-147) 290 51 (28-93) 235 38 (21-69) 193
50-59 99 (79-125) 830 47 (33-68) 668 34 (24-48) 559
60-69 188 (168-210) 2081 60 (48-74) 1532 49 (40-60) 1270
70-79 301 (283-321) 4093 97 (86-110) 2749 81 (72-92) 2201
80-89 459 (433-484) 3848 144 (128-162) 2240 130 (120-150) 1714
90+ 701 (634-776) 848 227 (182-283) 414 200 (160-250) 288
Table 3 Cox regression analysis for risk of re-MI or death
Time from initial AMI Risk factor Crude Hazard Ratio (95%CI) Adjusted Hazard Ratio (95%CI)
0-90 days Diabetes 1.3 (1.26-1.33) 1.16 (1.12-1.19)
Heart failure 2.6 (2.5-2.6) 1.6 (1.6-1.69)
Age group (per increase in decade) 1.06 (1.06-1.06) 1.04 (1.04-1.05)
Heart surgery for current MI 0.16 (0.15-0.17) 0.28 (0.27-0.3)
Female gender 1.6 (1.56-1.63) 1.0 (0.98-1.03)
91-180 days Diabetes 1.71 (1.6-1.8) 1.5 (1.4-1.6)
Heart failure 3.1 (2.96-3.2) 1.96 (1.86-2.1)
Age group (per increase in decade) 1.06 (1.06-1.07) 1.05 (1.04-1.05)
Heart surgery for current MI 0.24 (0.21-0.26) 0.42 (0.37-0.46)
Female gender 1.52 (1.4-1.6) 0.94 (0.9-1.0)
180-365 days Diabetes 1.66 (1.57-1.75) 1.5 (1.4-1.5)
Heart failure 3.06 (2.9-3.2) 1.93 (1.8-2.03)
Age group (per increase in decade) 1.066 (1.063-1.068) 1.055 (1.05-1.06)
Heart surgery for current MI 0.299 (0.27-0.32) 0.52 (0.47-0.57)
Female gender 1.5 (1.4-1.6) 0.94 (0.9-0.99)
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Page 6 of 8MI)), location of infarction (anterior, inferior) and type
of AMI (STEMI, non-STEMI). To improve survival
models linkage will be needed with primary care data-
sets where the most complete source of morbidity data
is held.
Conclusions
In summary, this study provides population based age
stratified absolute risks of re-infarction or death for peo-
ple with diabetes. These tables are based on all hospital
admissions in England and Wales for the period 2003-
2006 and these absolute risks can be used as reference
tables in clinical care, industry and in informing driving
legislation.
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Table 4 Rate of morality or infarction in controls (with no previous history of AMI) per 1,000 people
Gender Age 0-90 days: rate n 91-180 days: rate n 181-365 days: rate n
Male
30-39 0.46 226,251 0.38 225,283 0.71 224,530
40-49 0.85 210,842 0.78 210,255 1.8 209,697
50-59 2.3 202,353 2.16 201,602 4.7 200,923
60-69 4.9 149,269 5.06 148,381 11.7 147,462
70-79 13.3 102,893 12.45 101,414 29.07 100,052
80-89 30.0 40,259 26.99 39,019 68.78 37,922
90+ 58.7 5,061 52.64 4,758 125.55 4,487
Female 30-39 0.17 219,185 0.17 218,507 0.3942 217,754
40-49 0.46 203,768 0.57 203,322 1.05 202,860
50-59 1.40 199,492 1.13 198,944 2.39 198,432
60-69 3.02 153,572 2.93 152,927 6.88 152,294
70-79 8.42 127,186 8.22 125,988 19.44 124,827
80-89 21.96 75,909 21.37 74,142 52.52 72,464
90+ 54.88 16,421 50.26 15,505 128.61 14,718
Table 5 Relative risk of death or MI post hospitalization for MI
0-90 days
(95%CI)
91-180 days
(95%CI)
181-365 days
(95%CI)
0-90 days
(95%CI)
91-180 days
(95%CI)
181-365 days
(95%CI)
Male Female
No 30-39 43.1 (29.1-63.7) 23.9 (13.3-42.9) 6.76 (3.0-15.3) No 30-39 148.6 (71.5-308.5) 64.3 (20.7-200) 13.1 (2.3-73.6)
diabetes 40-49 28.3 (23.1-34.7) 12.2 (9.1-16.2) 4.9 (3.7-6.6) diabetes 40-49 82.3 (59.8-113.3) 24.2 (14.9-39.4) 9.4 (5.2-17.1)
50-59 18.6 (16.5-20.9) 5.2 (4.3-6.2) 1.8 (1.5-2.2) 50-59 42.8 (36.1-50.9) 14.0 (10.2-19) 5.0 (3.5-7.2)
60-69 18.0 (16.5-19.6) 4.7 (4.2-5.3) 1.6 (1.5-1.9) 60-69 33.1 (29.6-37.2) 8.3 (6.9-10.1) 3.1 (2.5-3.8)
70-79 16.1 (15.1-17.0) 4.5 (4.1-4.9) 1.7 (1.5-1.8) 70-79 27.5 (25.7-29.4) 6.5 (5.9-7.2) 2.3 (2.1-2.6)
80-89 14.1 (13.2-14.9) 4.2 (3.8-4.6) 1.6 (1.5-1.7) 80-89 19.3 (18.3-20.3) 4.8 (4.4-5.2) 1.7 (1.6-1.9)
90+ 12.5 (11.2-19.6) 3.8 (3.2-4.5) 1.5 (1.3-1.8) 90+ 11.8 (11-12.6) 3.2 (2.9-3.7) 1.1 (0.97-1.2)
Diabetes 30-39 41.0 (13.6-123.3) 75.4 (29-196.2) 7.5 (0.6-84) Diabetes 30-39 518 (217-1235) 122 (18.7-798.8) 152 (47.6-487.3)
40-49 62.1 (45.9-84.0) 15.2 (7.9-29) 13.5 (8.3-21.8) 40-49 218 (146-325) 90.7 (50.9-161.6) 35.9 (17.4-74.1)
50-59 38.0 (32.6-44.2) 12.8 (9.8-16.7) 4.7 (3.5-6.5) 50-59 71 (56-90) 41.9 (29.0-60.3) 14.3 (9.1-22.3)
60-69 31.4 (28.4-34.7) 9.2 (7.7-10.8) 3.9 (3.3-4.7) 60-69 62.2 (54.8-70.7) 21.03 (17.0-26.1) 7.1 (5.5-9.1)
70-79 21.9 (20.6-23.4) 7.2 (6.4-8.1) 2.5 (2.3-2.9) 70-79 35.8 (33.2-38.6) 11.8 (10.4-13.5) 4.2 (3.6-4.8)
80-89 15.1 (14.1-16.1) 6.4 (5.8-7.2) 2.1 (1.9-2.5) 80-89 20.9 (19.7-22.1) 6.74 (6.0-7.5) 2.5 (2.2-2.8)
90+ 11.9 (10.5-13.6) 5.7 (4.5-7.3) 1.5 (1.0-2.2) 90+ 12.8 (11.8-13.8) 4.5 (3.7-5.4) 1.5 (1.2-2.0)
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